RCC Update from ESMO 2023

Prof. Laurence Albiges joined us at ESMO 2023 to share her views on the latest renal cell carcinoma (RCC) data presented at the congress. She reviewed data from the following studies: LBA87 - Phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC) LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomised open-label phase 3 LITESPARK-005 study 1881O - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomised phase 2 LITESPARK-013 study 1882O - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomised, open-label, phase 3 study 1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) 1884MO - Phase 2 study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study Watch her video update and download the accompanying slides for a detailed summary here: https://cor2ed.com/gu-connect/program... The medical expert in this video is expressing their own views and not those of COR2ED, supporters, or their institution. This video is supported by an Independent Medical Education Grant from Eisai Europe Limited. October 2023